SCHEMBL407625

SCHEMBL407625

CCOC(=O)CC(OCC)(OCC)OCC

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.50
MGAM O43451 1/20 0.50
SI P14410 1/20 0.50
MGAM2 Q2M2H8 1/20 0.50
ALDH1A1 P00352 3/20 0.46
TRPA1 O75762 1/20 0.46
LMNA P02545 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP1A2 P05177 1/20 0.40
GSK3A P49840 1/20 0.39
GSK3B P49841 1/20 0.39
ALOX15 P16050 1/20 0.39
SOAT1 P35610 1/20 0.39
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
HSD11B1 P28845 1/20 0.36
ELANE P08246 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8158517 0.81 GAA (0.50) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL10595181 0.79 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL8918311 0.79 GAA (0.48) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL2208577 0.77 CYP1A2 (0.47) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL28373015 0.77 GAA (0.46) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL2836974 0.76 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL4440571 0.76 GAA (0.44) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL8975301 0.75 ALDH1A1 (0.38) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL232993 0.75 GAA (0.55) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL21052480 0.75 GAA (0.55) GAAMGAMSIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122090716-A Nameplate, preparation method thereof and photovoltaic module 2026-05-26 CN disclosed
CN-116676025-A Anti-flooding and anti-aging solid paint 四川瑞仕嘉科技有限公司 2023-09-01 CN disclosed
CN-1956998-B Method for the purification of albumin conjugates CONJUCHEM INC 2012-12-12 CN disclosed
US-20120022234-A1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES BOUSQUET-GAGNON NATHALIE (CA) 2012-01-26 US disclosed
EP-2230257-A1 Method for the purification of albumin conjugates ConjuChem Biotechnologies Inc. (CA) 2010-09-22 EP disclosed
EP-2100904-B1 Solid phase for use in a method for the purification of albumin conjugates CONJUCHEM BIOTECHNOLOGIES INC (CA) 2010-07-07 EP disclosed
EP-2100904-A1 Solid phase for use in a method for the purification of albumin conjugates ConjuChem Biotechnologies Inc. (CA) 2009-09-16 EP disclosed
EP-1745078-B1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES CONJUCHEM BIOTECHNOLOGIES INC (CA) 2009-06-17 EP disclosed
US-20080146783-A1 Method for the purification of albumin conjugates CONJUCHEM BIOTECHNOLOGIES INC. 2008-06-19 US disclosed
US-7307148-B2 Method for purification of albumin conjugates CONJUCHEM BIOTECHNOLOGIES INC. (CA) 2007-12-11 US disclosed
EP-1745078-A4 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES CONJUCHEM BIOTECHNOLOGIES INC (CA) 2007-08-01 EP disclosed
CN-1956998-A Method for the purification of albumin conjugates CONJUCHEM INC (CA) 2007-05-02 CN disclosed
EP-1745078-A1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES ConjuChem Biotechnologies Inc. (CA) 2007-01-24 EP disclosed
CN-1280253-C Method for preparing 3,3-diethoxy ethyl acrylate UNIV WUHAN (CN) 2006-10-18 CN disclosed
US-20050267293-A1 Method for purification of albumin conjugates CONJUCHEM, INC. (CA) 2005-12-01 US disclosed
WO-2005103087-A1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES CONJUCHEM BIOTECHNOLOGIES INC. (CA) 2005-11-03 WO disclosed
CN-1687010-A Method for preparing 3,3-diethoxy ethyl acrylate UNIV WUHAN (CN) 2005-10-26 CN disclosed
WO-2003059356-A2 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022234-A1 METHOD FOR THE PURIFICATION OF ALBUMIN CONJUGATES ALB, DNPEP, SLC7A1 GAA 1078/4885MGAM 1450/4885SI 171/4885
US-20050267293-A1 Method for purification of albumin conjugates ALB, DNPEP, SLC7A1 GAA 1163/4885MGAM 1618/4885SI 200/4885
US-20080146783-A1 Method for the purification of albumin conjugates ALB, DNPEP, SLC7A1 GAA 1078/4885MGAM 1450/4885SI 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.